Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

BACKGROUND: In this study, we evaluated real-world data on radium-223 plus abiraterone/prednisone or enzalutamide. Previously, the ERA 223 trial (NCT02043678) demonstrated increased fracture risk with concurrent treatment with radium-223 and abiraterone plus prednisone/prednisolone in patients with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate Cancer Prostatic Dis
Autors principals: Shore, Neal, Higano, Celestia S., George, Daniel J., Sternberg, Cora N., Saad, Fred, Tombal, Bertrand, Miller, Kurt, Kalinovsky, Jan, Jiao, XiaoLong, Tangirala, Krishna, Sartor, Oliver
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7655504/
https://ncbi.nlm.nih.gov/pubmed/32404868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-020-0236-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars